
WILSON AND GISVOLD'S

Textbook of Organic Medicinal and Pharmaceutical Chemistry

Ninth Edition

EDITED BY

Jaime N. Delgado, Ph.D.

Division of Medicinal Chemistry, College of Pharmacy
University of Texas at Austin, Austin, Texas

AND

William A. Remers, Ph.D.

Department of Pharmaceutical Sciences, College of Pharmacy
University of Arizona, Tucson, Arizona

17 Contributors



J. B. Lippincott Company Philadelphia
New York London Hagerstown

Production Manager: Janet Greenwood
Acquisitions Editor: Lisa McAllister
Manuscript Editor: Marguerite Hague
Production: Till & Till, Inc.
Compositor: Science Typographers, Inc.
Printer/Binder: The Murray Printing Company

Ninth Edition

Copyright © 1991, by J. B. Lippincott Company
Copyright © 1982 by J. B. Lippincott Company
Copyright © 1977, 1971, 1966, 1962, 1956 by J. B. Lippincott Company
Copyright © 1954 by J. B. Lippincott Company
All rights reserved. No part of this book may be used or reproduced in any manner whatsoever without written permission except for brief quotations embodied in critical articles and reviews. Printed in the United States of America. For information write J. B. Lippincott Company, East Washington Square, Philadelphia, Pennsylvania 19105.

6 5 4 3 2 1

Library of Congress Cataloging in Publication Data

Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry. — 9th ed. / edited by Jaime N. Delgado and William A. Remers : 17 contributors.
p. cm.
Includes bibliographical references.
Includes index.
ISBN 0-397-50877-8
1. Chemistry, Pharmaceutical. 2. Chemistry, Organic. I. Wilson, Charles Owens, 1911 – . II. Gisvold, Ole, 1904 – . III. Delgado, Jaime N. IV. Remers, William A. (William Alan), 1932 –
V. Title: Textbook of organic medicinal and pharmaceutical chemistry.
[DNLM: 1. Chemistry, Pharmaceutical. QV 744 W754]
RS403.T43 1991
615'.19 — dc20
DNLM/DLC
for Library of Congress

90-13652
CIP

The authors and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

CHAPTER 2

Physicochemical Properties in Relation to Biologic Action

John H. Block

INTRODUCTION

Modern drug design, as compared with, *Let's make a change on an existing compound or synthesize a new structure and see what happens*, is a fairly recent discipline still in its infancy. It is based on modern chemical techniques utilizing recent knowledge of disease mechanisms and receptor properties. A good understanding of how the drug is transported into the body, distributed throughout the body compartments, metabolically altered by the liver and other organs, and excreted from the patient is required, along with the structural characteristics of the receptor. Acid-base chemistry is utilized to aid in formulation and biodistribution. Those structural attributes and substituent patterns responsible for optimum pharmacologic activity can be predicted many times by statistical techniques, such as regression analysis. Conformational analysis permits the medicinal chemist to predict the drug's three-dimensional shape that is *seen* by the receptor. With the isolation and structural determination of specific receptors and the availability of computer software that can estimate the three-dimensional shape of the receptor, it is possible to design molecules that will show an optimum fit to the receptor.

HISTORY

Initially, drugs were extracted from plant sources to obtain agents such as digitalis, quinine, and morphine, medicinal agents that are still in use today. Specific plants are selected by the chemist because the crude preparations were being used for treatment of medical conditions by the local population where the plant grew.

Early drug design started with elucidation of the structure of the natural product, followed by selective changes in the molecule. The latter was done for many reasons, including the reduction of an undesirable pharmacologic response (side effect); obtaining a better pharmacokinetic response; altering the drug's metabolism; securing a more plentiful, less costly supply; and producing a competing product. Let us use the morphine alkaloid as an example. Literally thousands of compounds have been synthesized in an attempt to separate the desired analgesia from the undesirable addiction liability. This tremendous effort in numerous research laboratories, over many years and involving many scientists, had been minimally successful until a better understanding of the opiate receptor developed (see Chap. 9).

In other examples, there has been good success at this empirical approach. Alteration of the cocaine structure has led to the very successful local anesthetics that lack cocaine's undesirable central effects (see Chap. 15). In contrast with this success story, there have been no significant commercial synthetic replacements for digitalis or colchicine.

Synthetic medicinal chemistry as a discipline became more intense in the 1900s, but many of the so-called principal compounds still were based on a natural product, a fortuitous observation, or an unsuspected chemical reaction. The phenothiazines (see Chap. 9) were first synthesized as antihistamines, but a careful pharmacologic evaluation led to their use as major tranquilizing agents that revolutionized the care of the severely mentally ill patient. The benzodiazepines (see Chap. 9) originated from an unexpected ring enlargement and resulted in a very important group of central nervous system relaxants.

Economic factors have stimulated the type of scientific investigations required to carry out focused

new drug development. It has become increasingly costly to develop a new drug that will be approved by the U. S. Food and Drug Administration (FDA). At one time, safety was the main criterion for FDA approval. Today, demonstration of efficacy is an essential requirement, along with safety considerations. This has led to (1) increased basic research on the disease process for which a drug treatment is sought, (2) mathematically modeling the pharmacokinetics of the drug's distribution, (3) elucidation of the biochemistry of the pharmacologic response from the drug, (4) learning the metabolic fate of the drug, (5) defining those specific structural characteristics of the drug responsible for the desired pharmacologic response, and (6), where possible, visualizing the structural characteristics of the receptor. Although the number of new compounds introduced annually has decreased from earlier years, the products now coming into use are showing dramatic effects in the treatment of disease. More importantly, because of the intensive background investi-

gation that has led to the design of today's new agents, a better understanding of the drug's mechanism of action is known. Indeed, this is an exciting time to practice pharmacy.

OVERVIEW

A drug is a chemical molecule. Following introduction into the body, a drug must pass through many barriers, survive alternate sites of attachment and storage, and avoid significant metabolic destruction before it reaches the site of action, usually a receptor on or in a cell (Fig. 2-1). At the receptor, the following equilibrium usually holds.





FIG. 2-1. Summary of drug distribution: Solid bars: Drug must pass through membranes. Broken lines: Drug administered directly into systemic circulation.


The ideal drug molecule will show favorable-binding characteristics to the receptor, such that the equilibrium lies to the right. At the same time the drug will be expected to dissociate from the receptor and reenter systemic circulation to be excreted. The major exceptions include the alkylating agents used in cancer chemotherapy (see Chap. 8) and a few inhibitors of the enzyme, acetylcholinesterase (see Chap. 12). Both of these subclasses of pharmacologic agents form covalent bonds with the receptor. In these cases the cell must destroy the receptor or, as with the alkylating agents, the cell would be replaced, ideally with a normal cell. In other words, the usual use of drugs in medical treatment call for the drug's effect to last for only a finite period. Then, if it is to be repeated, the drug will be administered again. If the patient does not tolerate the drug well, it is even more important that the agent dissociate from the receptor and be excreted from the body.

DRUG DISTRIBUTION

ORAL ADMINISTRATION


An examination of the *obstacle course* (see Fig. 2-1) faced by the drug will give a better understanding of what is involved in developing a commercially feasible product. Assume that the drug is administered orally. The drug must go into solution for it to pass through the gastrointestinal mucosa. Even drugs administered as true solutions may not remain in solution as they enter the acidic stomach and then pass into the alkaline intestinal tract. (This will be explained further in the discussion on acid-base chemistry.) The ability of the drug to dissolve is governed by several factors, including its chemical structure, variation in particle size and particle surface area, nature of the crystal form, type of coating, and type of tablet matrix. By varying the formulation containing the drug and physical characteristics of the drug, it is possible to have a drug dissolve quickly or slowly, the latter being the situation for many of the sustained-action products. An example is orally administered sodium phenytoin; for which variation of both the crystal form and tablet adjuvants can significantly alter the bioavailability of this drug, which is widely used in the treatment of epilepsy.

Chemical modification is also used to a limited extent. For example, sulfasalazine, used in the treatment of ulcerative colitis, passes through a substantial portion of the intestinal tract before being metabolized to sulfapyridine and 5-aminosalicylic acid. The latter compound is believed to be the active agent for the treatment of ulcerative colitis.



Any compound passing through the gastrointestinal tract will encounter the many and various digestive enzymes that, in theory, can degrade the drug molecule. In practice, when a new drug entity is under investigation, it will probably be dropped for further consideration if it is found unable to survive in the intestinal tract. An exception would be a drug for which there is no other effective product available, or one that provides a more effective treatment over existing products and can be administered by an alternate route, usually parenteral.

In contrast, these same digestive enzymes can be used to advantage. Chloramphenicol is water-soluble enough that it comes in contact with the taste receptors on the tongue, producing an unpalatable bitterness. To mask this intense bitter taste, the palmitic acid moiety is added as an ester of the chloramphenicol's primary alcohol. This reduces the parent drug's water solubility so much that it can be formulated as a suspension that passes over the bitter taste receptors on the tongue. Once in the intestinal tract, the ester linkage is hydrolyzed by the digestive esterases to the active antibiotic, chloramphenicol, and the very common dietary fatty acid, palmitic acid.



Chloramphenicol: R = H;



Sulfasalazine and chloramphenicol palmitate are examples of *prodrugs*. Most prodrugs are compounds that are inactive in their native form, but are easily metabolized to the active agent. Sulfasalazine and chloramphenicol palmitate are examples of prodrugs that are cleaved to smaller compounds, one of which will be the active drug. Others are metabolic precursors to the active form. An example of this type of prodrug is menadione, a simple naphthoquinone, which is converted in the liver to vitamin K₂₍₂₀₎.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.